- Home
- PHM vs GH Comparison
PHM vs GH Comparison
Compare PHM & GH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PHM | GH |
|---|---|---|
| Founded | 1950 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Homebuilding | Medical Specialities |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 23.7B | 22.9B |
| IPO Year | 1994 | 2018 |
Fundamental Metrics
Financial Performance| Metric | PHM | GH |
|---|---|---|
| Price | $119.48 | $176.29 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 13 | 19 |
| Target Price | ★ $136.23 | $119.79 |
| AVG Volume (30 Days) | 1.2M | ★ 1.7M |
| Earning Date | 04-23-2026 | 05-07-2026 |
| Dividend Yield | ★ 0.86% | N/A |
| EPS Growth | N/A | ★ 6.74 |
| EPS | ★ 4.27 | N/A |
| Revenue | N/A | ★ $982,021,000.00 |
| Revenue This Year | N/A | $33.30 |
| Revenue Next Year | $4.50 | $28.27 |
| P/E Ratio | $27.98 | ★ N/A |
| Revenue Growth | N/A | ★ 32.88 |
| 52 Week Low | $108.49 | $53.40 |
| 52 Week High | $144.50 | $176.58 |
Technical Indicators
Market Signals| Indicator | PHM | GH |
|---|---|---|
| Relative Strength Index (RSI) | 39.71 | 62.58 |
| Support Level | $114.87 | $153.88 |
| Resistance Level | $132.83 | N/A |
| Average True Range (ATR) | 2.70 | 8.60 |
| MACD | -0.77 | 0.34 |
| Stochastic Oscillator | 27.84 | 85.57 |
Price Performance
Historical ComparisonAbout PHM PulteGroup Inc.
PulteGroup Inc is a homebuilder in the United States. The company mainly builds single-family detached homes and offers products to entry-level, move-up, and active-adult buyers. It also offers homebuyers mortgage financing, title, and insurance agency services through its financial services segment.
About GH Guardant Health Inc.
Guardant Health, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company's main franchises are Guardant360 for genomic profiling of tumors, Reveal for molecular residual disease testing, and Shield for colorectal cancer screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.